Mechanistic Features and Therapeutic Implications Related to the MiRNAs and Wnt Signaling Regulatory in Breast Cancer

Talebi, M.; Talebi, M.; Farkhondeh, T.; Simal-Gandara, J.; Kopustinskiene, D.M.; Bernatoniene, J.; Samarghandian, S. Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin. Cancer Cell Int., 2021, 21(1), 214.
[http://dx.doi.org/10.1186/s12935-021-01906-y] [PMID: 33858433]

Talebi, M. Talebi, M.; Farkhondeh, T.; Mishra, G.; İlgün, S.; Samarghandian, S. New insights into the role of the Nrf2 signaling pathway in green tea catechin applications. Phytother. Res., 2021, 36(6), 3078-3112.
[http://dx.doi.org/10.1002/ptr.7033] [PMID: 33569875]

Biganzoli, L.; Battisti, N.M.L.; Wildiers, H.; McCartney, A.; Colloca, G.; Kunkler, I.H.; Cardoso, M.J.; Cheung, K.L.; de Glas, N.A.; Trimboli, R.M.; Korc-Grodzicki, B.; Soto-Perez-de-Celis, E.; Ponti, A.; Tsang, J.; Marotti, L.; Benn, K.; Aapro, M.S.; Brain, E.G.C. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol., 2021, 22(7), e327-e340.
[http://dx.doi.org/10.1016/S1470-2045(20)30741-5] [PMID: 34000244]

Talebi, M.; Talebi, M.; Farkhondeh, T.; Samarghandian, S. Molecular mechanism-based therapeutic properties of honey. Biomed. Pharmacother., 2020, 130, 110590.
[http://dx.doi.org/10.1016/j.biopha.2020.110590] [PMID: 32768885]

Ford, N.A.; Dunlap, S.M.; Wheatley, K.E.; Hursting, S.D. Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator microRNA-504. PLoS One, 2013, 8(6), e68089.
[http://dx.doi.org/10.1371/journal.pone.0068089] [PMID: 23840816]

Klopotowska, D.; Matuszyk, J.; Wietrzyk, J. Steroid hormone calcitriol and its analog tacalcitol inhibit miR-125b expression in a human breast cancer MCF-7 cell line. Steroids, 2019, 141, 70-75.
[http://dx.doi.org/10.1016/j.steroids.2018.11.014] [PMID: 30503385]

Kurozumi, S.; Yamaguchi, Y.; Kurosumi, M.; Ohira, M.; Matsumoto, H.; Horiguchi, J. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J. Hum. Genet., 2017, 62(1), 15-24.
[http://dx.doi.org/10.1038/jhg.2016.89] [PMID: 27439682]

Loh, H.Y.; Norman, B.P.; Lai, K.S.; Rahman, N.M.A.N.A.; Alitheen, N.B.M.; Osman, M.A. The regulatory role of MicroRNAs in Breast Cancer. Int. J. Mol. Sci., 2019, 20(19), 4940.
[http://dx.doi.org/10.3390/ijms20194940] [PMID: 31590453]

Martin-Orozco, E.; Sanchez-Fernandez, A.; Ortiz-Parra, I.; Ayala-San Nicolas, M. WNT signaling in tumors: The way to evade drugs and immunity. Front. Immunol., 2019, 10, 2854.
[http://dx.doi.org/10.3389/fimmu.2019.02854] [PMID: 31921125]

Farkhondeh, T.; Amirabadizadeh, A.; Aramjoo, H.; Llorens, S.; Roshanravan, B.; Saeedi, F.; Talebi, M.; Shakibaei, M.; Samarghandian, S. Impact of metformin on cancer biomarkers in non-diabetic cancer patients: A systematic review and meta-analysis of clinical trials. Curr. Oncol., 2021, 28(2), 1412-1423.
[http://dx.doi.org/10.3390/curroncol28020134] [PMID: 33917520]

Talebi, M.; Talebi, M.; Farkhondeh, T.; Samarghandian, S. Biological and therapeutic activities of thymoquinone: Focus on the Nrf2 signaling pathway. Phytother. Res., 2021, 35(4), 1739-1753.
[http://dx.doi.org/10.1002/ptr.6905] [PMID: 33051921]

Liu, L.; Zhang, Y.; Lu, J. The roles of long noncoding RNAs in breast cancer metastasis. Cell Death Dis., 2020, 11(9), 749.
[http://dx.doi.org/10.1038/s41419-020-02954-4] [PMID: 32929060]

Gong, C.; Qu, S.; Lv, X.B.; Liu, B.; Tan, W.; Nie, Y.; Su, F.; Liu, Q.; Yao, H.; Song, E. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nat. Commun., 2014, 5(1), 5406.
[http://dx.doi.org/10.1038/ncomms6406] [PMID: 25406648]

Liu, S.J.; Dang, H.X.; Lim, D.A.; Feng, F.Y.; Maher, C.A. Long noncoding RNAs in cancer metastasis. Nat. Rev. Cancer, 2021, 21(7), 446-460.
[http://dx.doi.org/10.1038/s41568-021-00353-1] [PMID: 33953369]

Pe, M.; Dorme, L.; Coens, C.; Basch, E.; Calvert, M.; Campbell, A.; Cleeland, C.; Cocks, K.; Collette, L.; Dirven, L.; Dueck, A.C.; Devlin, N.; Flechtner, H.H.; Gotay, C.; Griebsch, I.; Groenvold, M.; King, M.; Koller, M.; Malone, D.C.; Martinelli, F.; Mitchell, S.A.; Musoro, J.Z.; Oliver, K.; Piault-Louis, E.; Piccart, M.; Pimentel, F.L.; Quinten, C.; Reijneveld, J.C.; Sloan, J.; Velikova, G.; Bottomley, A. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol., 2018, 19(9), e459-e469.
[http://dx.doi.org/10.1016/S1470-2045(18)30418-2] [PMID: 30191850]

Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]

Cleator, S.; Heller, W.; Coombes, R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol., 2007, 8(3), 235-244.
[http://dx.doi.org/10.1016/S1470-2045(07)70074-8] [PMID: 17329194]

Dittmer, J. Breast cancer stem cells: Features, key drivers and treatment options. Semin. Cancer Biol., 2018, 53, 59-74.
[http://dx.doi.org/10.1016/j.semcancer.2018.07.007] [PMID: 30059727]

Furuya, K.; Sasaki, A.; Tsunoda, Y.; Tsuji, M.; Udaka, Y.; Oyamada, H.; Tsuchiya, H.; Oguchi, K. Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231. Hum. Cell, 2016, 29(2), 76-82.
[http://dx.doi.org/10.1007/s13577-015-0126-2] [PMID: 26573286]

Garmpis, N.; Damaskos, C.; Garmpi, A.; Nikolettos, K.; Dimitroulis, D.; Diamantis, E.; Farmaki, P.; Patsouras, A.; Voutyritsa, E.; Syllaios, A.; Zografos, C.G.; Antoniou, E.A.; Nikolettos, N.; Kostakis, A.; Kontzoglou, K.; Schizas, D.; Nonni, A. Molecular classification and future therapeutic challenges of triple-negative breast cancer. In Vivo, 2020, 34(4), 1715-1727.
[http://dx.doi.org/10.21873/invivo.11965] [PMID: 32606140]

Jiang, S.; Zhang, M.; Zhang, Y.; Zhou, W.; Zhu, T.; Ruan, Q.; Chen, H.; Fang, J.; Zhou, F.; Sun, J.; Yang, X. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun. Signal., 2019, 17(1), 109.
[http://dx.doi.org/10.1186/s12964-019-0419-2] [PMID: 31462314]

Medina, M.A.; Oza, G.; Sharma, A.; Arriaga, L.G.; Hernández Hernández, J.M.; Rotello, V.M.; Ramirez, J.T. Triple-negative breast cancer: A review of conventional and advanced therapeutic strategies. Int. J. Environ. Res. Public Health, 2020, 17(6), 2078.
[http://dx.doi.org/10.3390/ijerph17062078] [PMID: 32245065]

Chen, Z.; Pan, T.; Jiang, D.; Jin, L.; Geng, Y.; Feng, X.; Shen, A.; Zhang, L. The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-Mediated adriamycin resistance of breast cancer via the Wnt/β-Catenin signaling pathway. Mol. Ther. Nucleic Acids, 2020, 19, 1434-1448.
[http://dx.doi.org/10.1016/j.omtn.2020.01.030] [PMID: 32160712]

Samarghandian, S.; Hadjzadeh, M.A.R.; Afshari, J.T.; Hosseini, M. Antiproliferative activity and induction of apoptotic by ethanolic extract of Alpinia galanga rhizhome in human breast carcinoma cell line. BMC Complement. Altern. Med., 2014, 14(1), 192-192.
[http://dx.doi.org/10.1186/1472-6882-14-192] [PMID: 24935101]

Esteva, F.J.; Hubbard-Lucey, V.M.; Tang, J.; Pusztai, L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol., 2019, 20(3), e175-e186.
[http://dx.doi.org/10.1016/S1470-2045(19)30026-9] [PMID: 30842061]

Makhoul, I.; Montgomery, C.O.; Gaddy, D.; Suva, L.J. The best of both worlds — managing the cancer, saving the bone. Nat. Rev. Endocrinol., 2016, 12(1), 29-42.
[http://dx.doi.org/10.1038/nrendo.2015.185] [PMID: 26503674]

Abolghasemi, M.; Tehrani, S.S.; Yousefi, T.; Karimian, A.; Mahmoodpoor, A.; Ghamari, A.; Jadidi-Niaragh, F.; Yousefi, M.; Kafil, H.S.; Bastami, M.; Edalati, M.; Eyvazi, S.; Naghizadeh, M.; Targhazeh, N.; Yousefi, B.; Safa, A.; Majidinia, M.; Rameshknia, V. MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. J. Cell. Physiol., 2020, 235(6), 5008-5029.
[http://dx.doi.org/10.1002/jcp.29396] [PMID: 31724738]

Niu, T.; Zhang, W.; Xiao, W. MicroRNA regulation of cancer stem cells in the pathogenesis of breast cancer. Cancer Cell Int., 2021, 21(1), 31.
[http://dx.doi.org/10.1186/s12935-020-01716-8] [PMID: 33413418]

Jain, P.; Alahari, S.K. Breast cancer stem cells: A new challenge for breast cancer treatment. Front. Biosci., 2011, 16(1), 1824-1832.
[http://dx.doi.org/10.2741/3824] [PMID: 21196267]

Leal, J.A.; Lleonart, M.E. MicroRNAs and cancer stem cells: Therapeutic approaches and future perspectives. Cancer Lett., 2013, 338(1), 174-183.
[http://dx.doi.org/10.1016/j.canlet.2012.04.020] [PMID: 22554710]

Guo, W.; Ruth, L.; Gottesman, D.S. Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. Stem Cells Transl. Med., 2014, 3(8), 942-948.
[http://dx.doi.org/10.5966/sctm.2014-0020] [PMID: 24904174]

Ghasemi, F.; Sarabi, P.Z.; Athari, S.S.; Esmaeilzadeh, A. Therapeutics strategies against cancer stem cell in breast cancer. Int. J. Biochem. Cell Biol., 2019, 109, 76-81.
[http://dx.doi.org/10.1016/j.biocel.2019.01.015] [PMID: 30772480]

Roshanravan, B.; Yousefizadeh, S.; Apaydin Yildirim, B.; Farkhondeh, T.; Amirabadizadeh, A.; Ashrafizadeh, M.; Talebi, M.; Samarghandian, S. The effects of Berberis vulgaris L. and Berberis aristata L. in metabolic syndrome patients: a systematic and meta-analysis study. Arch. Physiol. Biochem., 2020, 1-12.
[http://dx.doi.org/10.1080/13813455.2020.1828482] [PMID: 33040642]

Kim, Y.S.; Farrar, W.; Colburn, N.H.; Milner, J.A. Cancer stem cells: potential target for bioactive food components. J. Nutr. Biochem., 2012, 23(7), 691-698.
[http://dx.doi.org/10.1016/j.jnutbio.2012.03.002] [PMID: 22704055]

Markowska, J.; Kojs, Z.; Twardawa, D. Cancer stem cells in targeted therapy. Curr. Gyneco. Oncol., 2018, 16(2), 96-100.
[http://dx.doi.org/10.15557/CGO.2018.0012]

Luo, M.; Clouthier, S.G.; Deol, Y.; Liu, S.; Nagrath, S.; Azizi, E.; Wicha, M.S. Breast cancer stem cells: current advances and clinical implications. Methods Mol. Biol., 2015, 1293, 1-49.
[http://dx.doi.org/10.1007/978-1-4939-2519-3_1] [PMID: 26040679]

Creighton, C.; Gibbons, D.L.; Kurie, J.M. The role of epithelial–mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag. Res., 2013, 5(1), 187-195.
[http://dx.doi.org/10.2147/CMAR.S35171] [PMID: 23986650]

Kotiyal, S.; Bhattacharya, S. Breast cancer stem cells, EMT and therapeutic targets. Biochem. Biophys. Res. Commun., 2014, 453(1), 112-116.
[http://dx.doi.org/10.1016/j.bbrc.2014.09.069] [PMID: 25261721]

Lu, W.; Kang, Y. Cell lineage determinants as regulators of breast cancer metastasis. Cancer Metastasis Rev., 2016, 35(4), 631-644.
[http://dx.doi.org/10.1007/s10555-016-9644-y] [PMID: 27866304]

Nusse, R.; Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 1982, 31(1), 99-109.
[http://dx.doi.org/10.1016/0092-8674(82)90409-3] [PMID: 6297757]

Farooqi, A.A.; Tang, J.Y.; Li, R.N.; Ismail, M.; Chang, Y.T.; Shu, C.W.; Yuan, S.S.F.; Liu, J.R.; Mansoor, Q.; Huang, C.J.; Chang, H.W. Epigenetic mechanisms in cancer: push and pull between kneaded erasers and fate writers. Int. J. Nanomed, 2015, 10, 3183-3191.
[PMID: 25995628]

Ashrafizadeh, M.; Ahmadi, Z.; Farkhondeh, T.; Samarghandian, S. Resveratrol targeting the Wnt signaling pathway: A focus on therapeutic activities. J. Cell. Physiol., 2020, 235(5), 4135-4145.
[http://dx.doi.org/10.1002/jcp.29327] [PMID: 31637721]

Ashrafizadeh, M.; Rafiei, H.; Mohammadinejad, R.; Farkhondeh, T.; Samarghandian, S. Wnt-regulating microRNAs role in gastric cancer malignancy. Life Sci., 2020, 250, 117547.
[http://dx.doi.org/10.1016/j.lfs.2020.117547] [PMID: 32173311]

Clevers, H.; Nusse, R. Wnt/β-catenin signaling and disease. Cell, 2012, 149(6), 1192-1205.
[http://dx.doi.org/10.1016/j.cell.2012.05.012] [PMID: 22682243]

Galluzzi, L.; Spranger, S.; Fuchs, E.; López-Soto, A. WNT signaling in cancer immunosurveillance. Trends Cell Biol., 2019, 29(1), 44-65.
[http://dx.doi.org/10.1016/j.tcb.2018.08.005] [PMID: 30220580]

Khawaled, S.; Nigita, G.; Distefano, R.; Oster, S.; Suh, S.S.; Smith, Y.; Khalaileh, A.; Peng, Y.; Croce, C.M.; Geiger, T.; Seewaldt, V.L.; Aqeilan, R.I. Pleiotropic tumor suppressor functions of WWOX antagonize metastasis. Signal Transduct. Target. Ther., 2020, 5(1), 43.
[http://dx.doi.org/10.1038/s41392-020-0136-8] [PMID: 32300104]

Farooqi, A.; Khalid, S.; Ahmad, A. Regulation of cell signaling pathways and miRNAs by resveratrol in different cancers. Int. J. Mol. Sci., 2018, 19(3), 652.
[http://dx.doi.org/10.3390/ijms19030652] [PMID: 29495357]

Farooqi, A.A.; Pinheiro, M.; Granja, A.; Farabegoli, F.; Reis, S.; Attar, R.; Sabitaliyevich, U.Y.; Xu, B.; Ahmad, A. EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways. Cancers, 2020, 12(4), 951.
[http://dx.doi.org/10.3390/cancers12040951] [PMID: 32290543]

Aaliyari-Serej, Z.; Ebrahimi, A.; Barazvan, B.; Ebrahimi-Kalan, A.; Hajiasgharzadeh, K.; Kazemi, T.; Baradaran, B. Recent advances in targeting of breast cancer stem cells based on biological concepts and drug delivery system modification. Adv. Pharm. Bull., 2020, 10(3), 338-349.
[http://dx.doi.org/10.34172/apb.2020.042] [PMID: 32665892]

Cai, Y.; He, J.; Zhang, D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. OncoTargets Ther., 2015, 8, 2657-2664.
[PMID: 26442763]

Ghandadi, M.; Valadan, R.; Mohammadi, H.; Akhtari, J.; Khodashenas, S.; Ashari, S. Wnt-β-catenin signaling pathway, the achilles’ heels of cancer multidrug resistance. Curr. Pharm. Des., 2019, 25(39), 4192-4207.
[http://dx.doi.org/10.2174/1381612825666191112142943] [PMID: 31721699]

Bao, B.; Azmi, A.S.; Ali, S.; Ahmad, A.; Li, Y.; Banerjee, S.; Kong, D.; Sarkar, F.H. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim. Biophys. Acta, 2012, 1826(2), 272-296.
[PMID: 22579961]

Pai, S.G.; Carneiro, B.A.; Mota, J.M.; Costa, R.; Leite, C.A.; Barroso-Sousa, R.; Kaplan, J.B.; Chae, Y.K.; Giles, F.J. Wnt/beta-catenin pathway: modulating anticancer immune response. J. Hematol. Oncol., 2017, 10(1), 101-101.
[http://dx.doi.org/10.1186/s13045-017-0471-6] [PMID: 28476164]

Patel, S.; Alam, A.; Pant, R.; Chattopadhyay, S. Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights. Front. Immunol., 2019, 10, 2872.
[http://dx.doi.org/10.3389/fimmu.2019.02872] [PMID: 31921137]

Liang, Q.; Li, W.; Zhao, Z.; Fu, Q. Advancement of Wnt signal pathway and the target of breast cancer. Open Life Sci., 2016, 11(1), 98-104.
[http://dx.doi.org/10.1515/biol-2016-0013]

Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75(5), 843-854.
[http://dx.doi.org/10.1016/0092-8674(93)90529-Y] [PMID: 8252621]

Pourbagher-Shahri, A.M.; Farkhondeh, T.; Ashrafizadeh, M.; Talebi, M.; Samargahndian, S. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades. Biomed. Pharmacother., 2021, 136, 111214.
[http://dx.doi.org/10.1016/j.biopha.2020.111214] [PMID: 33450488]

Escuin, D.; López-Vilaró, L.; Bell, O.; Mora, J.; Moral, A.; Pérez, J.I.; Arqueros, C.; Ramón y Cajal, T.; Lerma, E.; Barnadas, A. MicroRNA-1291 is associated with locoregional metastases in patients with early-stage breast cancer. Front. Genet., 2020, 11, 562114.
[http://dx.doi.org/10.3389/fgene.2020.562114] [PMID: 33343622]

Kim, N.H.; Kim, H.S.; Kim, N.G.; Lee, I.; Choi, H.S.; Li, X.Y.; Kang, S.E.; Cha, S.Y.; Ryu, J.K.; Na, J.M.; Park, C.; Kim, K.; Lee, S.; Gumbiner, B.M.; Yook, J.I.; Weiss, S.J. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal., 2011, 4(197), ra71.
[http://dx.doi.org/10.1126/scisignal.2001744] [PMID: 22045851]

Ashrafizadeh, M.; Ang, H.L.; Moghadam, E.R.; Mohammadi, S.; Zarrin, V.; Hushmandi, K.; Samarghandian, S.; Zarrabi, A.; Najafi, M.; Mohammadinejad, R.; Kumar, A.P. MicroRNAs and their influence on the zeb family: Mechanistic aspects and therapeutic applications in cancer therapy. Biomolecules, 2020, 10(7), 1040.
[http://dx.doi.org/10.3390/biom10071040] [PMID: 32664703]

Do Canto, L.M.; Marian, C.; Willey, S.; Sidawy, M.; Da Cunha, P.A.; Rone, J.D.; Li, X.; Gusev, Y.; Haddad, B.R. MicroRNA analysis of breast ductal fluid in breast cancer patients. Int. J. Oncol., 2016, 48(5), 2071-2078.
[http://dx.doi.org/10.3892/ijo.2016.3435] [PMID: 26984519]

Dvinge, H.; Git, A.; Gräf, S.; Salmon-Divon, M.; Curtis, C.; Sottoriva, A.; Zhao, Y.; Hirst, M.; Armisen, J.; Miska, E.A.; Chin, S.F.; Provenzano, E.; Turashvili, G.; Green, A.; Ellis, I.; Aparicio, S.; Caldas, C. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature, 2013, 497(7449), 378-382.
[http://dx.doi.org/10.1038/nature12108] [PMID: 23644459]

Kang, H. MicroRNA-Mediated health-promoting effects of phytochemicals. Int. J. Mol. Sci., 2019, 20(10), 2535.
[http://dx.doi.org/10.3390/ijms20102535] [PMID: 31126043]

Chin, A.R.; Fong, M.Y.; Somlo, G.; Wu, J.; Swiderski, P.; Wu, X.; Wang, S.E. Cross-kingdom inhibition of breast cancer growth by plant miR159. Cell Res., 2016, 26(2), 217-228.
[http://dx.doi.org/10.1038/cr.2016.13] [PMID: 26794868]

Dai, J.; Su, Y.; Zhong, S.; Cong, L.; Liu, B.; Yang, J.; Tao, Y.; He, Z.; Chen, C.; Jiang, Y. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct. Target. Ther., 2020, 5(1), 145.
[http://dx.doi.org/10.1038/s41392-020-00261-0] [PMID: 32759948]

Talebi, M. Kakouri, E.; Talebi, M.; Tarantilis, P.A.; Farkhondeh, T.; İlgün, S.; Pourbagher-Shahri, A.M.; Samarghandian, S. Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer’s disease. Expert Rev. Neurother., 2021, 21(6), 625-642.
[http://dx.doi.org/10.1080/14737175.2021.1923479] [PMID: 33910446]

Hayes, J.; Peruzzi, P.P.; Lawler, S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med., 2014, 20(8), 460-469.
[http://dx.doi.org/10.1016/j.molmed.2014.06.005] [PMID: 25027972]

Abd-Aziz, N.; Kamaruzman, N.I.; Poh, C.L. Development of micrornas as potential therapeutics against cancer. J. Oncol., 2020, 2020, 1-14.
[http://dx.doi.org/10.1155/2020/8029721] [PMID: 32733559]

Aggarwal, V.; Priyanka, K.; Tuli, H.S. Emergence of circulating micrornas in breast cancer as diagnostic and therapeutic efficacy biomarkers. Mol. Diagn. Ther., 2020, 24(2), 153-173.
[http://dx.doi.org/10.1007/s40291-020-00447-w] [PMID: 32067191]

Biersack, B. Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention. Noncoding RNA Res., 2016, 1(1), 12-34.
[http://dx.doi.org/10.1016/j.ncrna.2016.07.001] [PMID: 30159408]

Bhat, S.A.; Majid, S.; Hassan, T. MicroRNAs and its emerging role as breast cancer diagnostic marker- A review. Adv. Biomar. Sci. Technol., 2019, 1, 1-8.
[http://dx.doi.org/10.1016/j.abst.2019.05.001]

Das, P.K.; Siddika, M.A.; Asha, S.Y.; Aktar, S.; Rakib, M.A.; Khanam, J.A.; Pillai, S.; Islam, F. MicroRNAs, a promising target for breast cancer stem cells. Mol. Diagn. Ther., 2020, 24(1), 69-83.
[http://dx.doi.org/10.1007/s40291-019-00439-5] [PMID: 31758333]

Ahmad, A. Pathways to breast cancer recurrence. ISRN Oncol., 2013, 2013, 1-16.
[http://dx.doi.org/10.1155/2013/290568] [PMID: 23533807]

Naorem, L.D.; Muthaiyan, M.; Venkatesan, A. Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach. J. Cell. Physiol., 2019, 234(7), 11768-11779.
[http://dx.doi.org/10.1002/jcp.27839] [PMID: 30488443]

Talebi, M.; Zarshenas, M.; Yazdani, E.; Moein, M. Preparation and evaluation of possible antioxidant activities of Rose traditional tablet “[Qurs-e-Vard]” a selected Traditional Persian Medicine [TPM] formulation via various procedures. Curr. Drug Discov. Technol., 2020.
[PMID: 32990537]

Farkhondeh, T.; Llorens, S.; Pourbagher-Shahri, A.M.; Ashrafizadeh, M.; Talebi, M.; Shakibaei, M.; Samarghandian, S. An overview of the role of adipokines in cardiometabolic diseases. Molecules, 2020, 25(21), 5218.
[http://dx.doi.org/10.3390/molecules25215218] [PMID: 33182462]

Cervantes-Garduño, A.; Zampedri, C.; Espinosa, M.; Maldonado, V.; Melendez-Zajgla, J.; Ceballos-Cancino, G. MT4-MMP modulates the expression of miRNAs in breast cancer cells. Arch. Med. Res., 2018, 49(7), 471-478.
[http://dx.doi.org/10.1016/j.arcmed.2019.02.001] [PMID: 30792164]

Talebi, M.; Talebi, M.; Kakouri, E.; Farkhondeh, T.; Pourbagher-Shahri, A.M.; Tarantilis, P.A.; Samarghandian, S. Tantalizing role of p53 molecular pathways and its coherent medications in neurodegenerative diseases. Int. J. Biol. Macromol., 2021, 172, 93-103.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.01.042] [PMID: 33440210]

Dorling, L.; Carvalho, S.; Allen, J.; González-Neira, A.; Luccarini, C.; Wahlström, C.; Pooley, K.A.; Parsons, M.T.; Fortuno, C.; Wang, Q.; Bolla, M.K.; Dennis, J.; Keeman, R.; Alonso, M.R.; Álvarez, N.; Herraez, B.; Fernandez, V.; Núñez-Torres, R.; Osorio, A.; Valcich, J.; Li, M.; Törngren, T.; Harrington, P.A.; Baynes, C.; Conroy, D.M.; Decker, B.; Fachal, L.; Mavaddat, N.; Ahearn, T.; Aittomäki, K.; Antonenkova, N.N.; Arnold, N.; Arveux, P.; Ausems, M.G.E.M.; Auvinen, P.; Becher, H.; Beckmann, M.W.; Behrens, S.; Bermisheva, M. Białkowska, K.; Blomqvist, C.; Bogdanova, N.V.; Bogdanova-Markov, N.; Bojesen, S.E.; Bonanni, B.; Børresen-Dale, A.L.; Brauch, H.; Bremer, M.; Briceno, I.; Brüning, T.; Burwinkel, B.; Cameron, D.A.; Camp, N.J.; Campbell, A.; Carracedo, A.; Castelao, J.E.; Cessna, M.H.; Chanock, S.J.; Christiansen, H.; Collée, J.M.; Cordina-Duverger, E.; Cornelissen, S.; Czene, K.; Dörk, T.; Ekici, A.B.; Engel, C.; Eriksson, M.; Fasching, P.A.; Figueroa, J.; Flyger, H.; Försti, A.; Gabrielson, M.; Gago-Dominguez, M.; Georgoulias, V.; Gil, F.; Giles, G.G.; Glendon, G.; Garcia, E.B.G.; Alnæs, G.I.G.; Guénel, P.; Hadjisavvas, A.; Haeberle, L.; Hahnen, E.; Hall, P.; Hamann, U.; Harkness, E.F.; Hartikainen, J.M.; Hartman, M.; He, W.; Heemskerk-Gerritsen, B.A.M.; Hillemanns, P.; Hogervorst, F.B.L.; Hollestelle, A.; Ho, W.K.; Hooning, M.J.; Howell, A.; Humphreys, K.; Idris, F.; Jakubowska, A.; Jung, A.; Kapoor, P.M.; Kerin, M.J.; Khusnutdinova, E.; Kim, S.W.; Ko, Y.D.; Kosma, V.M.; Kristensen, V.N.; Kyriacou, K.; Lakeman, I.M.M.; Lee, J.W.; Lee, M.H.; Li, J.; Lindblom, A.; Lo, W.Y.; Loizidou, M.A.; Lophatananon, A.; Lubiński, J.; MacInnis, R.J.; Madsen, M.J.; Mannermaa, A.; Manoochehri, M.; Manoukian, S.; Margolin, S.; Martinez, M.E.; Maurer, T.; Mavroudis, D.; McLean, C.; Meindl, A.; Mensenkamp, A.R.; Michailidou, K.; Miller, N.; Mohd Taib, N.A.; Muir, K.; Mulligan, A.M.; Nevanlinna, H.; Newman, W.G.; Nordestgaard, B.G.; Ng, P.S.; Oosterwijk, J.C.; Park, S.K.; Park-Simon, T.W.; Perez, J.I.A.; Peterlongo, P.; Porteous, D.J.; Prajzendanc, K.; Prokofyeva, D.; Radice, P.; Rashid, M.U.; Rhenius, V.; Rookus, M.A.; Rüdiger, T.; Saloustros, E.; Sawyer, E.J.; Schmutzler, R.K.; Schneeweiss, A.; Schürmann, P.; Shah, M.; Sohn, C.; Southey, M.C.; Surowy, H.; Suvanto, M.; Thanasitthichai, S.; Tomlinson, I.; Torres, D.; Truong, T.; Tzardi, M.; Valova, Y.; van Asperen, C.J.; Van Dam, R.M.; van den Ouweland, A.M.W.; van der Kolk, L.E.; van Veen, E.M.; Wendt, C.; Williams, J.A.; Yang, X.R.; Yoon, S.Y.; Zamora, M.P.; Evans, D.G.; de la Hoya, M.; Simard, J.; Antoniou, A.C.; Borg, Å.; Andrulis, I.L.; Chang-Claude, J.; García-Closas, M.; Chenevix-Trench, G.; Milne, R.L.; Pharoah, P.D.P.; Schmidt, M.K.; Spurdle, A.B.; Vreeswijk, M.P.G.; Benitez, J.; Dunning, A.M.; Kvist, A.; Teo, S.H.; Devilee, P.; Easton, D.F. Breast cancer risk genes — association analysis in more than 113,000 women. N. Engl. J. Med., 2021, 384(5), 428-439.
[http://dx.doi.org/10.1056/NEJMoa1913948] [PMID: 33471991]

Liu, T.; Hu, K.; Zhao, Z.; Chen, G.; Ou, X.; Zhang, H.; Zhang, X.; Wei, X.; Wang, D.; Cui, M.; Liu, C. MicroRNA-1 down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt/β-catenin pathway. Oncotarget, 2015, 6(39), 41638-41649.
[http://dx.doi.org/10.18632/oncotarget.5873] [PMID: 26497855]

Akalay, I.; Tan, T.Z.; Kumar, P.; Janji, B.; Mami-Chouaib, F.; Charpy, C.; Vielh, P.; Larsen, A.K.; Thiery, J.P.; Sabbah, M.; Chouaib, S. Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene, 2015, 34(17), 2261-2271.
[http://dx.doi.org/10.1038/onc.2014.151] [PMID: 24931170]

Fan, M.; Sethuraman, A.; Brown, M.; Sun, W.; Pfeffer, L.M. Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. Breast Cancer Res. Treat., 2014, 146(3), 487-502.
[http://dx.doi.org/10.1007/s10549-014-3040-5] [PMID: 25001613]

Nair, M.G.; Prabhu, J.S.; Korlimarla, A.; Rajarajan, S. P S, H.; Kaul, R.; Alexander, A.; Raghavan, R.; B S, S.; T S, S. miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis. Cancer Med., 2020, 9(15), 5587-5597.
[http://dx.doi.org/10.1002/cam4.3183] [PMID: 32543775]

Du, Q.; Zhang, X.; Zhang, X.; Wei, M.; Xu, H.; Wang, S. Propofol inhibits proliferation and epithelial-mesenchymal transition of MCF-7 cells by suppressing miR-21 expression. Artif. Cells Nanomed. Biotechnol., 2019, 47(1), 1265-1271.
[http://dx.doi.org/10.1080/21691401.2019.1594000] [PMID: 30942630]

Ma, F.; Li, W.; Liu, C.; Li, W.; Yu, H.; Lei, B.; Ren, Y.; Li, Z.; Pang, D.; Qian, C. MiR-23a promotes TGF-β1-induced EMT and tumor metastasis in breast cancer cells by directly targeting CDH1 and activating Wnt/β-catenin signaling. Oncotarget, 2017, 8(41), 69538-69550.
[http://dx.doi.org/10.18632/oncotarget.18422] [PMID: 29050223]

Kong, L.Y.; Xue, M.; Zhang, Q.C.; Su, C.F. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway. Oncotarget, 2017, 8(9), 15507-15519.
[http://dx.doi.org/10.18632/oncotarget.14662] [PMID: 28099945]

Wu, R.; Zhao, B.; Ren, X.; Wu, S.; Liu, M.; Wang, Z.; Liu, W. MiR-27a-3p Targeting GSK3β promotes triple-negative breast cancer proliferation and migration through Wnt/β-Catenin PATHWAY. Cancer Manag. Res., 2020, 12, 6241-6249.
[http://dx.doi.org/10.2147/CMAR.S255419] [PMID: 32801869]

Miao, Y.; Wang, L.; Zhang, X.; Xing, R.G.; Zhou, W.W.; Liu, C.R.; Zhang, X.L.; Tian, L. miR-30a inhibits breast cancer progression through the Wnt/β-catenin pathway. Int. J. Clin. Exp. Pathol., 2019, 12(1), 241-250.
[PMID: 31933739]

García-Vazquez, R.; Ruiz-García, E.; Meneses García, A.; Astudillo-de la Vega, H.; Lara-Medina, F.; Alvarado-Miranda, A.; Maldonado-Martínez, H.; González-Barrios, J.A.; Campos-Parra, A.D.; Rodríguez Cuevas, S.; Marchat, L.A.; López-Camarillo, C. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol., 2017, 39(6), 1-6.
[http://dx.doi.org/10.1177/1010428317702899] [PMID: 28621239]

Lv, C.; Li, F.; Li, X.; Tian, Y.; Zhang, Y.; Sheng, X.; Song, Y.; Meng, Q.; Yuan, S.; Luan, L.; Andl, T.; Feng, X.; Jiao, B.; Xu, M.; Plikus, M.V.; Dai, X.; Lengner, C.; Cui, W.; Ren, F.; Shuai, J.; Millar, S.E.; Yu, Z. MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nat. Commun., 2017, 8(1), 1036.
[http://dx.doi.org/10.1038/s41467-017-01059-5] [PMID: 29051494]

Bonetti, P.; Climent, M.; Panebianco, F.; Tordonato, C.; Santoro, A.; Marzi, M.J.; Pelicci, P.G.; Ventura, A.; Nicassio, F. Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer. Oncogene, 2019, 38(3), 360-374.
[http://dx.doi.org/10.1038/s41388-018-0445-3] [PMID: 30093634]

Han, B.; Peng, X.; Cheng, D.; Zhu, Y.; Du, J.; Li, J.; Yu, X. Delphinidin suppresses breast carcinogenesis through the HOTAIR/micro RNA -34a axis. Cancer Sci., 2019, 110(10), 3089-3097.
[http://dx.doi.org/10.1111/cas.14133] [PMID: 31325197]

Si, W.; Li, Y.; Shao, H.; Hu, R.; Wang, W.; Zhang, K.; Yang, Q. MiR-34a inhibits breast cancer proliferation and progression by targeting wnt1 in wnt/β-catenin signaling pathway. Am. J. Med. Sci., 2016, 352(2), 191-199.
[http://dx.doi.org/10.1016/j.amjms.2016.05.002] [PMID: 27524218]

Gao, X.; Zhang, Y.; Zhang, Z.; Guo, S.; Chen, X.; Guo, Y. MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1. Sci. Rep., 2020, 10(1), 44.
[http://dx.doi.org/10.1038/s41598-019-56571-z] [PMID: 31913290]

Nie, J.; Jiang, H.C.; Zhou, Y.C.; Jiang, B.; He, W.J.; Wang, Y.F.; Dong, J. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT. Biosci. Biotechnol. Biochem., 2019, 83(6), 1062-1071.
[http://dx.doi.org/10.1080/09168451.2019.1584521] [PMID: 30950326]

Chen, Y.; Wu, N.; Liu, L.; Dong, H.; Liu, X. microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2. J. Cell. Mol. Med., 2020, 24(13), 7353-7369.
[http://dx.doi.org/10.1111/jcmm.15317] [PMID: 32558224]

Jiang, D.; Zhou, B.; Xiong, Y.; Cai, H. miR-135 regulated breast cancer proliferation and epithelial-mesenchymal transition acts by the Wnt/β-catenin signaling pathway. Int. J. Mol. Med., 2019, 43(4), 1623-1634.
[http://dx.doi.org/10.3892/ijmm.2019.4081] [PMID: 30720046]

Isobe, T.; Hisamori, S.; Hogan, D.J.; Zabala, M.; Hendrickson, D.G.; Dalerba, P.; Cai, S.; Scheeren, F.; Kuo, A.H.; Sikandar, S.S.; Lam, J.S.; Qian, D.; Dirbas, F.M.; Somlo, G.; Lao, K.; Brown, P.O.; Clarke, M.F.; Shimono, Y. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. eLife, 2014, 3, e01977.
[http://dx.doi.org/10.7554/eLife.01977] [PMID: 25406066]

García-Vázquez, R.; Marchat, L.A.; Ruíz-García, E.; Astudillo-de la Vega, H.; Meneses-García, A.; Arce-Salinas, C.; Bargallo-Rocha, E.; Carlos-Reyes, Á.; López-González, J.S.; Pérez-Plasencia, C.; Ramos-Payán, R.; Aguilar-Medina, M.; López-Camarillo, C. MicroRNA-143 is associated with pathological complete response and regulates multiple signaling proteins in breast cancer. Technol. Cancer Res. Treat., 2019, 18.
[http://dx.doi.org/10.1177/1533033819827309] [PMID: 30755102]

Gao, W.; Ge, S.; Sun, J. Ailanthone exerts anticancer effect by up-regulating miR-148a expression in MDA-MB-231 breast cancer cells and inhibiting proliferation, migration and invasion. Biomed. Pharmacother., 2019, 109, 1062-1069.
[http://dx.doi.org/10.1016/j.biopha.2018.10.114] [PMID: 30551356]

Jiang, Q.; He, M.; Ma, M.T.; Wu, H.Z.; Yu, Z.J.; Guan, S.; Jiang, L.Y.; Wang, Y.; Zheng, D.D.; Jin, F.; Wei, M.J. MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol. Rep., 2016, 35(3), 1425-1432.
[http://dx.doi.org/10.3892/or.2015.4502] [PMID: 26707142]

Mu, J.; Zhu, D.; Shen, Z.; Ning, S.; Liu, Y.; Chen, J.; Li, Y.; Li, Z. The repressive effect of miR-148a on Wnt/β-catenin signaling involved in Glabridin-induced anti-angiogenesis in human breast cancer cells. BMC Cancer, 2017, 17(1), 307.
[http://dx.doi.org/10.1186/s12885-017-3298-1] [PMID: 28464803]

Jiang, J.; Cheng, X. Circular RNA circABCC4 acts as a ceRNA of miR-154-5p to improve cell viability, migration and invasion of breast cancer cells in vitro. Cell Cycle, 2020, 19(20), 2653-2661.
[http://dx.doi.org/10.1080/15384101.2020.1815147] [PMID: 33023375]

Ahmad, A.; Sarkar, S.H.; Bitar, B.; Ali, S.; Aboukameel, A.; Sethi, S.; Li, Y.; Bao, B.; Kong, D.; Banerjee, S.; Padhye, S.B.; Sarkar, F.H. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol. Cancer Ther., 2012, 11(10), 2193-2201.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-0232-T] [PMID: 22821148]

Liu, F.; Liu, Y.; Shen, J.; Zhang, G.; Han, J. MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating Frizzled 5 expression. Oncotarget, 2016, 7(31), 49130-49142.
[http://dx.doi.org/10.18632/oncotarget.9734] [PMID: 27323393]

Ma, F.; Zhang, J.; Zhong, L.; Wang, L.; Liu, Y.; Wang, Y.; Peng, L.; Guo, B. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. Gene, 2014, 535(2), 191-197.
[http://dx.doi.org/10.1016/j.gene.2013.11.035] [PMID: 24315818]

Mohammadi-Yeganeh, S.; Paryan, M.; Arefian, E.; Vasei, M.; Ghanbarian, H.; Mahdian, R.; Karimipoor, M.; Soleimani, M. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol., 2016, 37(7), 8993-9000.
[http://dx.doi.org/10.1007/s13277-015-4513-9] [PMID: 26758430]

Cai, J.; Guan, H.; Fang, L.; Yang, Y.; Zhu, X.; Yuan, J.; Wu, J.; Li, M. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J. Clin. Invest., 2013, 123(2), 566-579.
[http://dx.doi.org/10.1172/JCI65871] [PMID: 23321667]

Mohammadi-Yeganeh, S.; Hosseini, V.; Paryan, M. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. J. Cell. Physiol., 2019, 234(10), 18317-18328.
[http://dx.doi.org/10.1002/jcp.28465] [PMID: 30945294]

Song, L.; Liu, D.; Wang, B.; He, J.; Zhang, S.; Dai, Z.; Ma, X.; Wang, X. miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway. Oncol. Rep., 2015, 34(1), 525-531.
[http://dx.doi.org/10.3892/or.2015.3965] [PMID: 25955111]

Mandal, S.; Gamit, N.; Varier, L.; Dharmarajan, A.; Warrier, S. Inhibition of breast cancer stem-like cells by a triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4 and suppression of miRNA-499a-5p. Life Sci., 2021, 265, 118854.
[http://dx.doi.org/10.1016/j.lfs.2020.118854] [PMID: 33278391]

Chi, Y.; Wang, F.; Zhang, T.; Xu, H.; Zhang, Y.; Shan, Z.; Wu, S.; Fan, Q.; Sun, Y. miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway. J. Cell. Mol. Med., 2019, 23(9), 6295-6307.
[http://dx.doi.org/10.1111/jcmm.14515] [PMID: 31273950]

He, S.Z.; Wang, Q. MicroRNA-548c-5p inhibits the proliferation of breast cancer cells through regulating Wnt/β-catenin signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2020, 24(7), 3795-3804.
[PMID: 32329856]

Gao, J.; Yu, S.R.; Yuan, Y.; Zhang, L.L.; Lu, J.W.; Feng, J.F.; Hu, S.N. Retracted: MicroRNA-590-5p functions as a tumor suppressor in breast cancer conferring inhibitory effects on cell migration, invasion, and epithelial–mesenchymal transition by downregulating the Wnt–β-catenin signaling pathway. J. Cell. Physiol., 2019, 234(2), 1827-1841.
[http://dx.doi.org/10.1002/jcp.27056] [PMID: 30191949]

El Helou, R.; Pinna, G.; Cabaud, O.; Wicinski, J.; Bhajun, R.; Guyon, L.; Rioualen, C.; Finetti, P.; Gros, A.; Mari, B.; Barbry, P.; Bertucci, F.; Bidaut, G.; Harel-Bellan, A.; Birnbaum, D.; Charafe-Jauffret, E.; Ginestier, C. miR-600 acts as a bimodal switch that regulates breast cancer stem cell fate through wnt signaling. Cell Rep., 2017, 18(9), 2256-2268.
[http://dx.doi.org/10.1016/j.celrep.2017.02.016] [PMID: 28249169]

Majumder, M.; Dunn, L.; Liu, L.; Hasan, A.; Vincent, K.; Brackstone, M.; Hess, D.; Lala, P.K. COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Sci. Rep., 2018, 8(1), 327.
[http://dx.doi.org/10.1038/s41598-017-18612-3] [PMID: 29321644]

Cao, T.; Xiao, T.; Huang, G.; Xu, Y.; Zhu, J.J.; Wang, K.; Ye, W.; Guan, H.; He, J.; Zheng, D. CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway. Oncotarget, 2017, 8(49), 84917-84927.
[http://dx.doi.org/10.18632/oncotarget.18171] [PMID: 29156693]

Liu, G.; Wang, P.; Zhang, H. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway. J. Gene Med., 2019, 21(12), e3129.
[http://dx.doi.org/10.1002/jgm.3129] [PMID: 31693779]

Cai, W.Y.; Wei, T.Z.; Luo, Q.C.; Wu, Q.W.; Liu, Q.F.; Yang, M.; Ye, G.D.; Wu, J.F.; Chen, Y.Y.; Sun, G.B.; Liu, Y.J.; Zhao, W.X.; Zhang, Z.M.; Li, B.A. The Wnt-β-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. J. Cell Sci., 2013, 126(Pt 13), 2877-2889.
[PMID: 23613467]

Fanale, D.; Amodeo, V.; Bazan, V.; Insalaco, L.; Incorvaia, L.; Barraco, N.; Castiglia, M.; Rizzo, S.; Santini, D.; Giordano, A.; Castorina, S.; Russo, A. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? Oncotarget, 2016, 7(20), 29321-29332.
[http://dx.doi.org/10.18632/oncotarget.8722] [PMID: 27081088]

Yazdani, E.; Talebi, M.; Zarshenas, M.M.; Moein, M. Evaluation of possible antioxidant activities of barberry solid formulation, a selected formulation from Traditional Persian Medicine (TPM) via various procedures. Biointerface Res. Appl. Chem., 2019, 9(6), 4517-4521.
[http://dx.doi.org/10.33263/BRIAC96.517521]

Farkhondeh, T.; Pourbagher-Shahri, A.M.; Azimi-Nezhad, M.; Forouzanfar, F.; Brockmueller, A.; Ashrafizadeh, M.; Talebi, M.; Shakibaei, M.; Samarghandian, S. Roles of NRF2 in gastric cancer: targeting for therapeutic strategies. Molecules, 2021, 26(11), 3157.
[http://dx.doi.org/10.3390/molecules26113157] [PMID: 34070502]

Gong, L.G.; Shi, J.C.; Shang, J.; Hao, J.G.; Du, X. Effect of miR-34a on resistance to sunitinib in breast cancer by regulating the Wnt/β-catenin signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(3), 1151-1157.
[PMID: 30779084]

Jia, Z.; Zhu, H.; Sun, H.; Hua, Y.; Zhang, G.; Jiang, J.; Wang, X. Adipose mesenchymal stem cell-derived exosomal microrna-1236 reduces resistance of breast cancer cells to cisplatin by suppressing SLC9a1 and the wnt/β-catenin signaling. Cancer Manag. Res., 2020, 12, 8733-8744.
[http://dx.doi.org/10.2147/CMAR.S270200] [PMID: 33061571]

Kim, S.J.; Oh, J.S.; Shin, J.Y.; Lee, K.D.; Sung, K.W.; Nam, S.J.; Chun, K.H. Development of microRNA-145 for therapeutic application in breast cancer. J. Control. Release, 2011, 155(3), 427-434.
[http://dx.doi.org/10.1016/j.jconrel.2011.06.026] [PMID: 21723890]

Cheng, S.; Huang, Y.; Lou, C.; He, Y.; Zhang, Y.; Zhang, Q. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation. Cancer Biol. Ther., 2019, 20(3), 328-337.
[http://dx.doi.org/10.1080/15384047.2018.1529101] [PMID: 30336071]

Eterno, V.; Zambelli, A.; Villani, L.; Tuscano, A.; Manera, S.; Spitaleri, A.; Pavesi, L.; Amato, A. AurkA controls self-renewal of breast cancer-initiating cells promoting WNT3a stabilization through suppression of miR-128. Sci. Rep., 2016, 6(1), 28436.
[http://dx.doi.org/10.1038/srep28436] [PMID: 27341528]

Gao, X.; Lai, Y.; Zhang, Z.; Ma, Y.; Luo, Z.; Li, Y.; Yang, C.; Lu, G.; Li, J. long non-coding rna rp11-480i12.5 promotes the proliferation, migration, and invasion of breast cancer cells through the mir-490-3p-aurka-wnt/β-catenin axis. Front. Oncol., 2020, 10, 948.
[http://dx.doi.org/10.3389/fonc.2020.00948] [PMID: 32733789]

Han, L.; Yan, Y.; Zhao, L.; Liu, Y.; Lv, X.; Zhang, L.; Zhao, Y.; Zhao, H.; He, M.; Wei, M. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a-3p/WNT1 pathway. J. Cell. Mol. Med., 2020, 24(11), 6242-6252.
[http://dx.doi.org/10.1111/jcmm.15261] [PMID: 32307830]

Huan, J.; Xing, L.; Lin, Q.; Xui, H.; Qin, X. Long noncoding RNA CRNDE activates Wnt/β-catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. Am. J. Transl. Res., 2017, 9(4), 1977-1989.
[PMID: 28469804]

Pan, Z.; Ding, J.; Yang, Z.; Li, H.; Ding, H.; Chen, Q. LncRNA FLVCR1-AS1 promotes proliferation, migration and activates Wnt/β-catenin pathway through miR-381-3p/CTNNB1 axis in breast cancer. Cancer Cell Int., 2020, 20(1), 214.
[http://dx.doi.org/10.1186/s12935-020-01247-2] [PMID: 32518523]

Li, P.; Guo, Y.; Bledsoe, G.; Yang, Z.; Chao, L.; Chao, J. Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp. Cell Res., 2016, 340(2), 305-314.
[http://dx.doi.org/10.1016/j.yexcr.2016.01.004] [PMID: 26790955]